Minority News
The world you see depends upon the news you get. ®
April 30, 2024
Susan G. Komen® Urges Personalized Approach in Response to Breast Cancer Screening Recommendations   •     •   KnowBe4 Partners With the Center for Cyber Safety and Education to Award $10,000 Scholarship To Empower Women in Cybersecurity   •     •   Aloe Blacc To Premiere "Shine" Honoring Aurora Humanitarians with Live Performance at Aurora Prize for Awakening Humanity Ceremo  •     •   Astria Learning Marks 15 Years of Pioneering Edtech Solutions Around the World   •     •   Canada Increases Support for Indigenous Participation in Critical Minerals Development and Supports Good Jobs in the Northwest T  •     •   Nine-year-old Southern California Leukemia Survivor Will Meet Donor Who Saved Her Life at City of Hope’s Bone Marrow Trans  •     •   Performance Food Group Company Releases 2023 Environmental, Social and Governance Report   •     •   Toyota and Argonne National Laboratory Investigate Recycling of Lithium-Ion Batteries   •     •   TA Studios Set to Showcase Innovative Virtual Reality Projects at Augmented World Expo in Long Beach   •     •   U.S. News & World Report Honors 20 Belmont Village Senior Living Communities in its 2024-2025 Best Senior Living List   •     •   Gap Inc. Releases 2023 ESG Report, Sharing Progress on Sustainability and Inclusion   •     •   2024 Flinn Scholars to Receive Full Rides to Arizona Public Universities   •     •   BOOST Transforms Big Ten Conference Website   •     •   Applications Open: Statewide Community of Practice on DEI Focusing on Developmental Disabilities   •     •   American Water Charitable Foundation Awards $1 Million through 2024 Water and Environment Grant Program   •     •   SIPPS and Being a Reader Small-Group Reading Meet the Requirements of the Virginia Literacy Act   •     •   Gen Z Students Declare “This Is The Way” to Champion Accessibility, Preserve Endangered Indigenous Languages & S  •     •   Groundbreaking Report Reveals Untold Stories of AANHPI Girls and Gender-Expansive Youth Leadership   •     •   Brookdale HealthPlus Earns Best of the Best Award from Argentum   •     •   World Renowned Dementia Care Expert Teepa Snow Comes to Maplewood at Stony Hill for Day of Learning   •  
HOME SEARCH SUBSCRIBE CONTACT

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

WATERTOWN, Mass. , April 17 /Businesswire/ - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”

Abstract Number: 02980

Poster Number: PO423

Day: April 27, 2024

Time: 12:00 p.m. CEST / 6:00 a.m. ET

Session Location: Poster Area

Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.